Brussels, 22/07/2016 (Agence Europe) - The European Medicines Agency sees no objection to extending the marketing authorisation for Truvada. The Committee for Medicinal products for Human Use (CHMP) took the view on Thursday 21 July that this medicine could also be used as part of a prevention strategy.
The CHMP opinion will now be sent to the European Commission which has the final say on the matter.
Truvada is a medicine produced by American laboratory Gilead. It contains two active...